A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis

2004 ◽  
Vol 13 (4) ◽  
pp. 805-811 ◽  
Author(s):  
E. McColl ◽  
S.W. Han ◽  
J.R. Barton ◽  
M.R. Welfare
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Discriminatory Power ◽  
Inflammatory Bowel Disease Questionnaire ◽  
Sf 36 ◽  
Inflammatory Bowel ◽  
Disease Questionnaire

scholarly journals Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies

2020 ◽  
Author(s):  
Marla C Dubinsky ◽  
Marco DiBonaventura ◽  
Haiyun Fan ◽  
Andrew G Bushmakin ◽  
Joseph C Cappelleri ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Janus Kinase ◽  
Effect Sizes ◽  
Phase 3 ◽  
Inflammatory Bowel Disease Questionnaire ◽  
Bowel Symptoms ◽  
Inflammatory Bowel ◽  
Disease Questionnaire

Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We examined the effect of tofacitinib induction treatment on Inflammatory Bowel Disease Questionnaire (IBDQ) items in adults with moderate to severe UC. Methods Data were pooled from the randomized, 8‑week, double-blind, phase 3 OCTAVE Induction 1 and 2 studies. The IBDQ was self-administered by patients at baseline, week 4, and week 8, with higher scores indicating better health-related quality of life (HRQoL). Change from baseline in IBDQ items was analyzed for 10 mg of tofacitinib twice daily (BID) vs placebo using a linear mixed-effects model, with no multiplicity adjustment performed. Effect sizes were calculated. Subgroup analyses by tumor necrosis factor inhibitor (TNFi) experience were performed. Results Significant improvements (nominal P < 0.05) were observed in all IBDQ items with 10 mg of tofacitinib BID vs placebo at weeks 4 and 8. For the overall population, the largest treatment differences across all items were reported for “bowel movements been loose” at weeks 4 and 8, and “problem with rectal bleeding” at week 8 (mean treatment differences all 1.1; both in bowel symptoms domain). These items also showed the largest effect sizes. Treatment benefits were generally slightly numerically higher in TNFi-experienced vs TNFi-naïve patients. Conclusions Tofacitinib induction therapy improved all IBDQ items vs placebo in patients with UC, reflecting improvements in HRQoL, with greatest benefits reported in bowel symptoms domain items (Funded by Pfizer Inc; OCTAVE Induction 1 and OCTAVE Induction 2; ClinicalTrials.gov, NCT01465763 and NCT01458951, respectively).

scholarly journals Calidad de vida en pacientes con enfermedad de Crohn ileocecal posterior a tratamiento quirúrgico.

2021 ◽  
Author(s):  
Nicolas Avellaneda ◽  
Pablo Muñoz ◽  
Mariano Vaingurt ◽  
Fernando Vazquez ◽  
Analia Potolicchio ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Short Form ◽  
Inflammatory Bowel Disease Questionnaire ◽  
Enfermedad De Crohn ◽  
Short Form 36 ◽  
Calidad De Vida ◽  
Sf 36 ◽  
Inflammatory Bowel ◽  
Disease Questionnaire

Introducción: La localización ileocecal es la más frecuente en la enfermedad de Crohn y muchos de estos pacientes requieren tratamiento quirúrgico durante la evolución de su enfermedad. Existe escasa evidencia sobre el impacto del mismo en la calidad vida de estos enfermos.Materiales y métodos: Se llevó a cabo un estudio retrospectivo sobre una base de datos prospectiva, incluyendo los pacientes operados durante un período de 30 meses por enfermedad de Crohn con compromiso ileocecal. Como variable de resultado primaria se evaluó la calidad de vida de los mismos antes y 4 meses después de la cirugía usando dos cuestionarios validados (Short Form-36, Inflammatory Bowel Disease Questionnaire). También se evaluó la morbilidad de los procedimientos.Resultados: Se incluyeron en el estudio 19 pacientes. La edad media fue de 34 años (23-72), 18 pacientes fueron operados por vía laparoscópica y 2 pacientes requirieron re operación. La media de seguimiento fue de 16 meses (4 - 30). Tres pacientes (16%) presentaron complicaciones mayores. Los resultados obtenidos en este estudio muestran una mejoría promedio de 46% en los parámetros valorados por el cuestionario SF-36 (p=0.0001) y de 81 puntos (p=0.0001) en los valores del cuestionario IBDQ luego del tratamiento operatorio.Conclusión: El tratamiento quirúrgico de la enfermedad de Crohn con compromiso ileocecal presenta buenos resultados después del tratamiento quirúrgico y una mejora significativa en la calidad de vida de los pacientes.

scholarly journals Cultural Adaptation and Validation of the Inflammatory Bowel Disease Disability Index in a Spanish Population and Its Association with Sociodemographic and Clinical Factors

2019 ◽  
Vol 16 (4) ◽  
pp. 635 ◽  
Author(s):  
Rafael López-Cortés ◽  
Raquel Herrero-Hahn ◽  
Rosanna De la Rosa-Eduardo ◽  
Rafael Montoya-Juárez ◽  
María García-Caro ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cultural Adaptation ◽  
Spanish Population ◽  
Clinical Factors ◽  
Inflammatory Bowel Disease Questionnaire ◽  
Inflammatory Bowel ◽  
Disease Questionnaire ◽  
Active Disease

Inflammatory bowel diseases generate disability. We aimed to adapt and validate the Inflammatory Bowel Disease Disability Index in a Spanish population and to analyze the sociodemographic and clinical factors associated with disability in patients with Crohn’s disease and ulcerative colitis. Cultural adaptation and validation of psychometric properties in the index were done, along with an observational, cross-sectional, and analytical approach to determine associations with sociodemographic and clinical factors. Sociodemographic data, quality of life (using the Inflammatory Bowel Disease Questionnaire-32), and indicators of disease activity were collected, among others. A total of 170 subjects participated. The index showed high internal consistency, with a Cronbach’s alpha of 0.869 and concurrent validity with the Inflammatory Bowel Disease Questionnaire-32 (r = 0.723, p < 0.001). The average score of the index was −3.91. Greater degrees of disability were found in women (mean = −6.77) than in men (mean = −1.25) (p = 0.018), in patients with Crohn’s disease (mean = −5.94) rather than those with ulcerative colitis (mean = −0.94) (p = 0.028), and in patients in the moderately active disease phase (mean = −20.94) rather than those in the mildly active disease phase (mean = −2.65) and/or those in remission (mean = −1.40) (p < 0.001). The Disability Index is a valid tool for the Spanish population and is associated with sex, type of illness, and disease activity. It is a useful index in evaluating and monitoring disability in patients with inflammatory bowel disease.

Sign in / Sign up

Export Citation Format

Share Document